ストックスクリーナーアプリを入手
5.41
7.20%
-0.42
プレマーケット:
5.49
0.08
+1.48%
Kalaris Therapeutics Inc (KLRS) 最新ニュース
Kalaris Therapeutics restructures executive compensation By Investing.com - Investing.com South Africa
Kalaris Therapeutics restructures executive compensation - Investing.com
Kalaris Therapeutics Amends Executive Employment Agreements - TipRanks
Kalaris Therapeutics initiated with an Outperform at William Blair - MSN
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-The-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses - MarketScreener
William Blair initiates Kalaris stock with Outperform rating By Investing.com - Investing.com UK
William Blair Initiates Kalaris Therapeutics With Outperform Rating - marketscreener.com
Kalaris Therapeutics appoints new board chair By Investing.com - Investing.com Canada
The Gross Law Firm Notifies Shareholders of AlloVir, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2024(NASDAQ: ALVR) - MarketScreener
Kalaris Therapeutics appoints new board member - Investing.com Australia
Kalaris Therapeutics Appoints Leone Patterson to Board - TipRanks
Kalaris Therapeutics appoints new board member By Investing.com - Investing.com Canada
Kalaris Therapeutics appoints new board chair - Investing.com Australia
Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee - marketscreener.com
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - TradingView
Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation - 01net
ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - MarketScreener
ALVR Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - MarketScreener
KLRS stock touches 52-week low at $7.75 amid market challenges - Investing.com
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - MarketScreener
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionALVR - MarketScreener
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact Levi & Korsinsky - MarketScreener
ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 - Investing.com India
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 By Investing.com - Investing.com UK
Kalaris and AlloVir Inc. complete merger - Ophthalmology Times
Kalaris Therapeutics Announces Closing of Merger With AlloVir - VisionMonday.com
ALLOVIR, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against AlloVir, Inc. - Marketscreener.com
Kalaris Therapeutics Completes Merger with AlloVir -March 19, 2025 at 04:18 am EDT - Marketscreener.com
AlloVir Merges with Kalaris Therapeutics, Inc. - TipRanks
Kalaris Therapeutics Completes Merger with AlloVir, Advances Phase 1 Trial of TH103 for Neovascular Retina Diseases - Nasdaq
Kalaris Secures $100M War Chest for Revolutionary Macular Degeneration Treatment - StockTitan
Shootin' the Bull about cattle feeders - The Globe and Mail
Kalaris and AlloVir Announce Stockholder Approval of Merger - VisionMonday.com
AlloVir shareholders approve merger with Kalaris Therapeutics By Investing.com - Investing.com India
Stockholders Approve Game-Changing Kalaris-AlloVir Merger: What This Means for Retinal Disease Treatment - StockTitan
Allovir, Inc. SEC 10-K Report - TradingView
Allovir’s chief accounting officer sells $967 in stock - Investing.com India
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire
Allovir director Vikas Sinha sells $1,225 in stock - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATSG, CYTH, ALVR on Behalf of Shareholders - Finansavisen
AlloVir executes reverse stock split - Investing.com
Allovir stock plunges to 52-week low, touches $0.4 - Investing.com
AlloVir announces reverse stock split effective January 16 - Investing.com
AlloVir shareholders approve reverse stock split - Investing.com
AlloVir appoints new CEO following leadership shakeup - Investing.com
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - insights.citeline.com
AlloVir Ditches Immunotherapy, Teams Up with Kalaris to Take Over the $14 Billion Retinal Market - BioSpectrum Asia
Kalaris Therapeutics - The Pharma Letter
Kalaris to merge with AlloVir to become publicly traded company - World Pharmaceutical Frontiers
ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders - Business Wire
The McMullan Team - William Blair
Class Action Filed Against AlloVir, Inc. (ALVR)March 19, 2024 Deadline to JoinContact Levi & Korsinsky - MarketScreener
symbol__ Stock Quote Price and Forecast - CNN
0.39%
3.66%
大文字化:
|
ボリューム (24 時間):